U.S. equities experienced a notable pullback in afternoon trading on Wednesday, September 24, 2025, as a robust multi-day rally lost momentum. Major indexes drifted lower, with investors taking profits and digesting recent comments from Federal Reserve Chair Jerome Powell regarding elevated asset valuations. While the broader market saw a pause, specific sectors and individual stocks demonstrated significant movements, highlighting ongoing themes of artificial intelligence investment and shifting economic s ...

PresentationGood day, and welcome to the top line results for AMT-130 in Huntington's disease. [Operator Instructions] As a reminder, this call may be recorded. I would now like to turn the call over to Chiara Russo, Senior Director, Investor Relations.Chiara Russo Thank you. This morning, uniQure announced pivotal data on patients treated with our investigational gene therapy, AMT-130 in our ongoing Phase I/II clinical trials in Huntington's disease, taking place in the U.S., EU and the U.K. This 3-year u ...

股价表现 - 公司股价在周三开盘时上涨近200%，成为生物技术行业今年最剧烈的单日波动之一 [1] 积极进展 - 股价飙升源于三方面利好消息的推动 [1]

智通财经APP获悉，周三，uniQure(QURE.US)暴涨超186%，创四年新高，报39.11美元。消息面上，9 月24日，该公司宣布与Hercules Capital达成1.75亿美元非稀释性高级担保定期贷款协议，包括现有5000 万美元债务再融资，额外1.25亿美元融资可提取，利息率降至9.70%，显著改善财务灵活性。此外，该 公司公布AMT-130在亨廷顿病1/2期关键研究中达到主要终点，高剂量组36个月数据显示疾病进展减缓 75%cUHDRS测量，同时关键次要终点TFC测量显示疾病进展减缓60%。 ...

周三，uniQure(QURE.US)暴涨超186%，创四年新高，报39.11美元。消息面上，9月24日，该公司宣布 与Hercules Capital达成1.75亿美元非稀释性高级担保定期贷款协议，包括现有5000万美元债务再融资， 额外1.25亿美元融资可提取，利息率降至9.70%，显著改善财务灵活性。此外，该公司公布AMT-130在 亨廷顿病1/2期关键研究中达到主要终点，高剂量组36个月数据显示疾病进展减缓75%cUHDRS测量，同 时关键次要终点TFC测量显示疾病进展减缓60%。 ...

uniQure N.V. QURE on Wednesday released topline data from the pivotal Phase 1/2 study of AMT-130 for Huntington’s disease.Huntington’s disease is an inherited condition in which nerve cells in the brain break down over time. The disease affects a person’s movements, thinking ability and mental health.The study met its prespecified primary endpoint, with high-dose AMT-130 demonstrating a statistically significant slowing of disease progression as measured by the composite Unified Huntington’s Disease Rating ...

uniQure (NasdaqGS:QURE) Update / Briefing September 24, 2025 08:30 AM ET Company ParticipantsChiara Russo - Senior Director - IRMatt Kapusta - CEO & Executive DirectorWalid Abi-Saab - Chief Medical OfficerSarah Tabrizi - ProfessorKylie O’Keefe - Chief Customer & Strategy OfficerPaul Matteis - MD & Head - Therapeutics ResearchJoseph Schwartz - Senior MD - Rare DiseasesDebjit Chattopadhyay - Senior Managing DirectorUy Ear - VP of US Healthcare - BiotechnologySalveen Richter - Biotechnology Equity ResearchElli ...

Pivotal Phase I/II AMT-130 Huntington's Disease Update September 24, 2025 Disclaimer This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may ...

uniQure (NASDAQ:QURE) announced on Wednesday that its one-time gene therapy AMT-130 reached the main goals in a pivotal Phase 2/3 trial for patients with Huntington’s disease, a rare neurodegenerative disorder. Citing topline data from the trial, the Dutch biotech noted that ...

UniQure's experimental gene therapy significantly slowed the progression of a brain disorder in an early-to-mid stage study, it said on Wednesday. ...